186 related articles for article (PubMed ID: 35236735)
1. Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracycline/cyclophosphamide regimen (JTOP-B).
Ozeki R; Iihara H; Shimokawa M; Hashimoto H; Abe M; Mukohara T; Bando H; Hayashi T; Kawazoe H; Komoda M; Yanai Takahashi T; Saito M
BMJ Open; 2022 Mar; 12(3):e058755. PubMed ID: 35236735
[TBL] [Abstract][Full Text] [Related]
2. Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients.
Iihara H; Shimokawa M; Abe M; Hayasaki Y; Fujita Y; Nagasawa Y; Sakurai M; Matsuoka R; Suzuki A; Morishige K
BMJ Open; 2019 Jan; 9(1):e024357. PubMed ID: 30782732
[TBL] [Abstract][Full Text] [Related]
3. Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy.
Minatogawa H; Izawa N; Kawaguchi T; Miyaji T; Shimomura K; Kazunori H; Iihara H; Ohno Y; Inada Y; Arioka H; Morita H; Hida N; Sugawara M; Katada C; Nawata S; Ishida H; Tsuboya A; Tsuda T; Yamaguchi T; Nakajima TE
BMJ Open; 2020 Dec; 10(12):e041737. PubMed ID: 33334838
[TBL] [Abstract][Full Text] [Related]
4. Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B).
Sakai H; Tsurutani J; Ozaki Y; Ishiguro H; Nozawa K; Watanabe K; Maeda S; Yokoe T; Imamura CK; Matsumoto K; Iwasa T; Chiba Y; Takiguchi D; Takano T
BMJ Open; 2023 Apr; 13(4):e070304. PubMed ID: 37012013
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.
Zhang Z; Zhang Y; Chen G; Hong S; Yang Y; Fang W; Luo F; Chen X; Ma Y; Zhao Y; Zhan J; Xue C; Hou X; Zhou T; Ma S; Gao F; Huang Y; Chen L; Zhou N; Zhao H; Zhang L
Oncologist; 2018 May; 23(5):603-616. PubMed ID: 29330211
[TBL] [Abstract][Full Text] [Related]
7. Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.
Kosaka Y; Tanino H; Sengoku N; Minatani N; Kikuchi M; Nishimiya H; Waraya M; Katoh H; Enomoto T; Sato T; Kuranami M; Watanabe M
Support Care Cancer; 2016 Mar; 24(3):1405-11. PubMed ID: 26349772
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial.
Iihara H; Shimokawa M; Gomyo T; Fujita Y; Yoshida T; Funaguchi N; Minato K; Kaito D; Osawa T; Yamada M; Hirose C; Suzuki A; Ohno Y
BMJ Open; 2019 Jul; 9(7):e028056. PubMed ID: 31278102
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting.
Clemons M; Dranitsaris G; Sienkiewicz M; Sehdev S; Ng T; Robinson A; Mates M; Hsu T; McGee S; Freedman O; Kumar V; Fergusson D; Hutton B; Vandermeer L; Hilton J
Breast; 2020 Dec; 54():278-285. PubMed ID: 33242754
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Secondary Analysis of the J-FORCE Randomized Clinical Trial.
Abe M; Yamaguchi T; Fujita Y; Nishimura T; Kitagawa K; Inui N; Hirano K; Sakata Y; Iihara H; Shibuya Y; Suzuki K; Shibata K; Hori K; Daga H; Nakayama T; Sakata Y; Takahashi TY; Zenda S; Hashimoto H
JAMA Netw Open; 2023 May; 6(5):e2310894. PubMed ID: 37129897
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
12. Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial.
Bajpai J; Kapu V; Rath S; Kumar S; Sekar A; Patil P; Siddiqui A; Anne S; Pawar A; Srinivas S; Bhargava P; Gulia S; Noronha V; Joshi A; Prabhash K; Banavali S; Sarin R; Badwe R; Gupta S
Lancet Oncol; 2024 Feb; 25(2):246-254. PubMed ID: 38224701
[TBL] [Abstract][Full Text] [Related]
13. Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain.
Escobar Álvarez Y; De Castro Carpeño J; Bell D; Drago A; Franceschetti A
Clin Transl Oncol; 2021 Oct; 23(10):2155-2162. PubMed ID: 33956310
[TBL] [Abstract][Full Text] [Related]
14. Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy.
Inui N
Med Oncol; 2017 May; 34(5):77. PubMed ID: 28365889
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.
Chanthawong S; Lim YH; Subongkot S; Chan A; Andalusia R; Ahmad Bustamam RS; Chaiyakunapruk N
Support Care Cancer; 2019 Mar; 27(3):1109-1119. PubMed ID: 30112718
[TBL] [Abstract][Full Text] [Related]
16. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.
Aapro M; Scotté F; Escobar Y; Celio L; Berman R; Franceschetti A; Bell D; Jordan K
Oncologist; 2021 Jun; 26(6):e1073-e1082. PubMed ID: 33555084
[TBL] [Abstract][Full Text] [Related]
17. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602).
Navari RM; Le-Rademacher J; Smieliauskas F; Ruddy KJ; James Saphner T; Liu H; Harlos E; Onitilo AA; Giridhar K; Paul Singh P; Reddy PS; Chow S; Kruter F; Raptis G; Loprinzi CL
Oncologist; 2023 Aug; 28(8):722-729. PubMed ID: 37284847
[TBL] [Abstract][Full Text] [Related]
19. Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.
Nawa-Nishigaki M; Kobayashi R; Suzuki A; Hirose C; Matsuoka R; Mori R; Futamura M; Sugiyama T; Yoshida K; Itoh Y
Anticancer Res; 2018 Feb; 38(2):877-884. PubMed ID: 29374715
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis.
Filetti M; Lombardi P; Giusti R; Falcone R; Scotte F; Giannarelli D; Carcagnì A; Altamura V; Scambia G; Daniele G
Cancer Treat Rev; 2023 Apr; 115():102512. PubMed ID: 36774658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
